FOX04-DRI 10mg

Sold as a lypholized powder

FOXO4-DRI (sometimes written incorrectly as “FOX04-DRI”) is an experimental senolytic peptide being studied for its ability to selectively eliminate senescent cells—older or damaged cells that have stopped dividing but remain metabolically active.

🧬 What it is being researched for:

• 🧹 Senescent cell removal: FOXO4-DRI disrupts the interaction between FOXO4 and p53, allowing p53-dependent apoptosis (programmed cell death) to occur preferentially in senescent cells.
• ⏳ Aging and longevity research: Because senescent cells accumulate with age and can disrupt normal tissue function, researchers are investigating whether clearing them can improve age-related tissue health.
• 🔥 Age-related inflammation: Senescent cells can produce inflammatory signaling molecules known collectively as the SASP. Removing these cells is being investigated as a way of reducing their detrimental effects on surrounding tissues.
• ❤️ Vascular aging: Recent animal and cell research found FOXO4-DRI promoted removal of senescent endothelial cells and improved measures of vascular function in aged mice.
• 🦴 Tissue regeneration: Laboratory research has examined FOXO4-DRI for removing senescent cartilage cells, potentially improving the quality of cartilage generated from cultured chondrocytes.
• 🧪 Other experimental applications: It has also been investigated in animal or laboratory models involving age-related Leydig-cell dysfunction and senescent fibroblasts.

How FOXO4-DRI works

Think of senescent cells as damaged cells that refuse to shut themselves down. FOXO4 helps these cells survive partly through its interaction with p53. FOXO4-DRI is designed to interfere with that interaction, enabling p53 signaling to push the senescent cell toward apoptosis.

⚠️ Important: FOXO4-DRI remains experimental. The evidence is predominantly from cell and animal studies, so claims that it reverses aging or provides established anti-aging benefits in humans are not supported by clinical evidence yet.